Our Team

Dr Moore’s four decade career has focused on the regulation of cell production in the body’s two most regenerative tissues: the bone marrow and the single layer of the intestinal mucosa.

His PhD research conducted at the US National Institutes of Health (NIH) changed the origin of the genetic basis of paroxysmal nocturnal haemaglobinuria (PNH).

Dr Moore’s search for regulators of cell production started as a post-doctoral fellow of Prof Don Metcalf at the Walter and Elisa Hall Institute (WEHI) in Melbourne, the founder of the field of blood cell production.

Based on some early research, Dr Moore set out at WEHI to identify the body’s regulators that protect stem cells (engine for cell production) from the toxicity of chemotherapy. The search continued at DNAX Research Institute in Palo Alto and at ImClone Systems Inc in New York City.

At ImClone, Dr Moore discovered a protein (FRIL) that maintained blood stem cells in culture for extended periods and were capable of repopulating long-term blood cell production. He founded Phylogix Inc in the Boston area and advanced FRIL to late preclinical development with $15m venture capital funding from Atlas Venture, Biotechnology Value Fund, Canaan Partners, Prospect Venture Partners and Radius Ventures.

Dr Moore then moved to the body’s other most regenerative tissue, the mucosal layer of the gut. He joined Prof Chris Potten, founder of the epithelial stem cell field, at Epistem Ltd in Manchester, UK. Dr Moore created and led a regenerative medicine collaboration with Novartis Institutes of BioMedical Research (NIBR), where his team developed and validated in vitro models that delivered the core technology at Curileum.

Jeff received a PhD from George Washington University in Genetics from Washington University after obtaining a BA in Chemistry from Colorado College.

RJ leads the clinical programme for ULI262 at Curileum.

Hehas a clinical, drug development and management career in modifying the immunology and inflammation associated with transplantation, cancer autoimmune and neurodegenerative diseases.

For the last decade, he was founder, President and CEO of INmune Bio (NASDAQ: INMB) focused primarily on developing therapy targeting neuroinflammation as a cause of Alzheimer’s disease while overseeing programs using off-the-shelf cell therapies for treatment of castrate resistant metastatic prostate cancer (mCPRC) and Recessive Dystrophic Epidermolysis Bullosa (RDEB).

Previously, Dr. Tesi held positions in public and private biotech companies. He has been involved in developing therapies for transplantation, autoimmune disease, treatment of cancer and neurodegenerative diseases. During this time he has been a principle in company founding, fund-raising, going public, investor relations and M&A. He has significant experience in product pre-clinical, clinical development, regulatory and commercialization of drugs including product positioning, clinical/regulatory strategy and execution, product launch and marketing.

Before joining industry, Dr. Tesi was an academic transplant surgeon with experience in liver, pancreas, kidney and small intestinal transplantation. Dr. Tesi has co-authored many peer-reviewed publications and has made presentations of medical/scientific topics at major conferences.

RJ received a medical degree from Washington University after obtaining a BA, cum laude from Utah State University.

Howard Levy, MBBCh, PhD brings over 25 years of experience in the pharmaceutical industry with a focus on critical care therapeutic areas and rare diseases. He practiced as an intensivist with specialty board certification in Internal Medicine, Pulmonary and Intensive Care, and Medical Management.

Since 2010 he has advised public and private biotechnology and medical device companies on clinical and drug development strategy and execution

Nate has lead the identification and the continued extensive physicochemical characterisation of ULI262.

He is an Emeritus Professor of Chemistry at Colorado College, where he spent four decades applying analytical chemistry to challenges spanning forensic science, environmental ecology, and analytical characterisation of rare materials.

Nate received a PhD from Oregon State University after receiving a BA from the College of Wooster.

Mohini leads the in vitro characterisation of ULI262 at Curileum.

She is the Lead Scientist with a broad expertise in cell biology. Before joining Curileum, she led complex bioanalytical projects at Synexa Life Sciences and contributed to the COVAC1 self-amplifying RNA vaccine trial at Imperial College London. Her work spans clinical trials in infectious disease and oncology, with publications in The Lancet, Journal of Clinical Investigation, and Cell Reports.

Mohini received a  MSc in Immunology (Distinction) from Imperial College London and a BA (Hons) in Biological Natural Sciences from the University of Cambridge.

Darren Dixon is Professor of Chemistry at the University of Oxford and a leading contributor in synthetic methodology. As CSO and Founder of Cortex Organics, he pioneers novel synthetic routes to complex molecules. His work bridges academic discovery with commercial application in drug development.

Yao Shi leads the synthesis of ULI262 at Curileum.

He is chemist and entrepreneur, serving as CEO and Founder of Cortex Organics. With a PhD in synthetic chemistry, he has developed innovative strategies for scalable synthesis of complex molecules. Yao leads Cortex in supporting pharma and biotech partners with bespoke chemistry solutions.

Yao received a PhD from the University of Oxford after obtaining MSc and BSc degrees from the Cambridge University in Organic Chemistry.

Paul Brennan is Professor of Medicinal Chemistry at Oxford and Director of the Centre for Medicines Discovery. His research focuses on chemical biology and drug discovery, particularly developing small molecules to probe disease pathways. He has extensive experience translating academic discovery into therapeutic innovation.

Sir John Burn is Professor of Clinical Genetics at Newcastle University and a Fellow of the Academy of Medical Sciences. A global authority in hereditary cancer syndromes, he has pioneered research and clinical practice in genomics, cancer prevention, and precision medicine.

Mark Hull is Professor of Molecular Gastroenterology at the University of Leeds and Co-Founder of COLO-PREVENT. His research emphasizes colorectal cancer prevention, inflammation-associated carcinogenesis, and translational clinical trials designed to test preventive interventions.